BioVaxys Technology (BioVaxys Technology) Current Accrued Expense : $0.05 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Current Accrued Expense?

BioVaxys Technology's Current Accrued Expense for the quarter that ended in Jul. 2023 was $0.05 Mil.

BioVaxys Technology's quarterly Current Accrued Expense declined from Jan. 2023 ($0.08 Mil) to Apr. 2023 ($0.05 Mil) and declined from Apr. 2023 ($0.05 Mil) to Jul. 2023 ($0.05 Mil).

BioVaxys Technology's annual Current Accrued Expense declined from Oct. 2020 ($0.04 Mil) to Oct. 2021 ($0.03 Mil) but then increased from Oct. 2021 ($0.03 Mil) to Oct. 2022 ($0.09 Mil).

BioVaxys Technology Current Accrued Expense Historical Data

The historical data trend for BioVaxys Technology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Current Accrued Expense Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Current Accrued Expense

0.04

0.01

0.04

0.03

0.09

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Current Accrued Expense	Get a 7-Day Free Trial															0.06	0.09	0.08	0.05	0.05

BioVaxys Technology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

BioVaxys Technology Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.